Physician profile
Matthew Bach
NPI 1669994745
$1,944.74
in general payments reported to CMS, 2019-2025
13 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $524 · 2024: $1,119 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $74.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.56 |
| Education | $74.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $354.68 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $324.72 | 2024-2025 | Rexulti |
| Abbvie INC. | $275.74 | 2023-2024 | |
| Corium, LLC | $181.92 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $172.58 | 2024-2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $163.20 | 2023 | Quviviq |
| Lundbeck LLC | $143.40 | 2024-2025 | Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $134.87 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.62 | 2023 | |
| Indivior INC. | $41.97 | 2024-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $29.08 | 2024 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $20.64 | 2024 | Trintellix |
| Avion Pharmaceuticals | $16.32 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.